INA’s response to the spread of COVID-19 (SARS-CoV-2) Novel Coronavirus infections in Japan
2020/03/25
With the health safety and security of all stakeholders including employees and customers as our top priority, SNBL INA (INA) has been implementing measures based on guidance received from government authorities in order to help prevent the spread of COVID-19 (SARS-CoV-2) infections. COVID-19 is the most urgent social concern in the world. However, comparing with European countries and US or China, the COVID-19 infection overshoot has not appeared in Japan as of today (March 25, 2020). Needless to say, we
Information about entering into an agency contract with SAGE HEALTHCARE PTE LTD.
2019/12/03
SNBL INA Co., Ltd. (hereinafter “the Company”) has decided today to enter into an agency contract with SAGE HEALTHCARE PTE LTD (hereinafter “SAGE”) in Singapore for the purpose of expanding sales of non-clinical studies focusing on pharmaceuticals. Information about entering into an agency contract with SAGE HEALTHCARE PTE LTD. – PDF (132KB)
Announcement concerning the start of agency business with ViruSure
2019/09/06
SNBL INA Ltd. (hereinafter referred to as “our company”) is pleased to announce that our company has decided to start the agency business for ViruSure (Austria : hereinafter referred to as “VS”), which is a contract research organization (hereinafter referred to as “CRO” ) in Japan and Taiwan today. (Please refer to the below PDF file for more details.) Announcement concerning the start of agency business with ViruSure GmbH (PDF: 128KB)
Agency Agreement with Level Biotechnology Inc., Taiwan
2019/08/07
SNBL INA Ltd. (INA) is pleased to announce the signing of an agency agreement with Level Biotechnology Inc. (LBI), a Taiwanese Contract Research Organization. 1.Market Potential The biopharmaceutical industry in Taiwan is currently growing at an unprecedented rate. With LBI as our locally-based agent, Taiwanese customers can now access INAs services in nonhuman primates, studies which are required as part of the biopharmaceutical development process. In this way, INA hopes to establish a mutually-complementary relationship with LBI, and make inroads
Tokyo University AMED iD3 Catalyst Unit posted about Grobal SEND Alliance.
2019/07/08
A column regarding to the Grobal SEND Alliance (G-SEND) was posted on the website of Tokyo University AMED iD3 Catalyst Unit. G-SEND is a non-profit consortium, consisting of CROs from Japan, South Korea, Taiwan, Singapore, the US and Switzerland. They provide SEND data sets which are created in a standardized process and Ina Reseach is the central CRO as their base. Please see the link below for the article: http://www.id3catalyst.jp/e/column03.html